Category: ADC Technologies

1. Conjugation of Lysine ResiduesThis method attaches the payload to the lysine residue of the antibody through a linker containing an active carboxylate site. 2.

Although the research history is short and there are few types of ADC drugs on the market, these drugs play an important role in the

1. Selection of toxic small molecules: Since the small molecules of ADCs require high toxicity, affinity, and low sensitivity to multidrug resistance protein (MDR1)-mediated efflux,

The ADC linker needs to have the following 4 basic characteristics to ensure the safety and effectiveness of the ADC:(1) Maintain high stability in blood

Structure is the key to achieving functionality. The structure of an ADC is obvious: antibody, linker, and coupled drug. Whether an ADC is successful or

The physicochemical properties of toxins directly affect the ability of ADCs to kill target cells. Therefore, ADC cytotoxins usually have the following characteristics:(1) The mechanism

The target identification of ADC drugs plays a decisive role in the drugability of ADCs. Qualified ADC targets should have:(1) Tissue specificity: In order to

The first generation: represented by Mylotarg, with high off-target toxicity and low drug efficacy Mylotarg It is the world’s first marketed ADC drug, the first

1. Pfizer: Pioneer in the field of ADC, launched the world’s first ADC drug Mylotarg Mylotarg (Gemtuzumabozogamicin, gemtuzumab) was originally developed by Pfizer. It is

1. Selection of the correct target The successful development of ADC relies on the specific binding of antibodies to the target antigen. The ideal ADC

Due to the advantages of clear targets, mature technology and good selectivity, the research of antibody-drug conjugates is expected to continue to become a research

The steps of ADC drug pharmacy include: Production of Linkers and Small Molecule Drugs as Drug Intermediates Conjugating linker-small molecule intermediates to antibodies Remove unlinked